These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34060347)

  • 1. Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats.
    Romero-Palomo F; Festag M; Lenz B; Schadt S; Brink A; Kipar A; Steinhuber B; Husser C; Koller E; Sewing S; Tessier Y; Dzygiel P; Fischer G; Winter M; Hetzel U; Mihatsch MJ; Braendli-Baiocco A
    Toxicol Pathol; 2021 Aug; 49(6):1174-1192. PubMed ID: 34060347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Metabolite Profiles of an
    Li XQ; Elebring M; Dahlén A; Weidolf L
    Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
    Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
    Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides.
    Uemura Y; Kobayashi K
    Drug Deliv; 2019 Dec; 26(1):803-811. PubMed ID: 31385541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
    Uemura Y; Hagiwara K; Kobayashi K
    PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bovine milk extracellular vesicles for the delivery of locked nucleic acid antisense oligonucleotides.
    Grossen P; Portmann M; Koller E; Duschmalé M; Minz T; Sewing S; Pandya NJ; van Geijtenbeek SK; Ducret A; Kusznir EA; Huber S; Berrera M; Lauer ME; Ringler P; Nordbo B; Jensen ML; Sladojevich F; Jagasia R; Alex R; Gamboni R; Keller M
    Eur J Pharm Biopharm; 2021 Jan; 158():198-210. PubMed ID: 33248268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a detection method for antisense oligonucleotides in mouse kidneys by matrix-assisted laser desorption/ionization imaging mass spectrometry.
    Yokoi H; Kasahara Y; Obika S; Doi T; Kamada H
    Rapid Commun Mass Spectrom; 2018 Dec; 32(23):1984-1990. PubMed ID: 30152908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
    Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
    Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of modular conjugation strategy for
    Yamamoto T; Sawamura M; Terada C; Kashiwada K; Wada F; Yamayoshi A; Obika S; Harada-Shiba M
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):109-118. PubMed ID: 31617782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.
    Laxton C; Brady K; Moschos S; Turnpenny P; Rawal J; Pryde DC; Sidders B; Corbau R; Pickford C; Murray EJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3105-14. PubMed ID: 21502629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
    Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
    Wang Y; Yu RZ; Henry S; Geary RS
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression.
    Buntz A; Killian T; Schmid D; Seul H; Brinkmann U; Ravn J; Lindholm M; Knoetgen H; Haucke V; Mundigl O
    Nucleic Acids Res; 2019 Jan; 47(2):953-969. PubMed ID: 30462278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
    Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides.
    Burdick AD; Sciabola S; Mantena SR; Hollingshead BD; Stanton R; Warneke JA; Zeng M; Martsen E; Medvedev A; Makarov SS; Reed LA; Davis JW; Whiteley LO
    Nucleic Acids Res; 2014 Apr; 42(8):4882-91. PubMed ID: 24550163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides.
    Yamamoto T; Mukai Y; Wada F; Terada C; Kayaba Y; Oh K; Yamayoshi A; Obika S; Harada-Shiba M
    Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34072682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
    Wada F; Yamamoto T; Kobayashi T; Tachibana K; Ito KR; Hamasaki M; Kayaba Y; Terada C; Yamayoshi A; Obika S; Harada-Shiba M
    Mol Ther Nucleic Acids; 2021 Dec; 26():957-969. PubMed ID: 34760338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.